A curated selection of organizations, government agencies, and private foundations that provide grants, subsidies, or non-dilutive capital to biotech innovators. This list focuses on funding sources that allow startups to retain equity while securing essential R&D resources.
Get targeted exposure with custom position pinning and highlighted placement.
A premier federal program across multiple agencies including NIH and NSF that awards competitive grants to small businesses for innovative R&D. It provides non-dilutive funding to help de-risk early-stage biotech technologies before they attract private investment.
Similar to SBIR but mandates a formal collaborative partnership between the small business and a rigorous research institution. This structure is ideal for biotech firms needing academic expertise alongside federal non-dilutive funding for translational research.
The cornerstone of biomedical research funding in the US, offering substantial non-dilutive support for basic and clinical research. While highly competitive, these grants are critical for establishing scientific validity and generating preliminary data for later-stage biotech ventures.
Provides strategic grants and flexible funding to scientists working on challenging problems in biology and medicine. CZI often funds early-stage innovation and community-building efforts without taking equity, focusing on accelerating scientific discovery in targeted therapeutic areas.
Offers significant grant funding aimed at improving global health and reducing extreme poverty, with a strong focus on infectious diseases and diagnostics. Their biotech grants often support innovations in developing regions or novel public health technologies.
Provides grant funding specifically for immuno-oncology research, supporting both established scientists and promising early-career researchers. They offer non-dilutive capital to advance innovative immunotherapy approaches and accelerate the development of cancer vaccines and treatments.
Offers several distinct grant programs supporting basic and translational research into Alzheimer's disease and related dementias. These non-dilutive funds help biotech firms and academic institutions explore novel therapeutic targets and diagnostic tools in a high-impact field.
A federal agency within the Department of Defense that funds high-risk, high-reward biotech innovations with national security applications. Their programs often support rapid prototyping and translation of emerging biomedical technologies for military and civilian use.
The UK's leading innovation agency providing grants and equity-free finance to help businesses grow and succeed. For biotech firms, they offer significant funding for R&D projects that demonstrate strong commercial potential and economic impact within the UK.
The EU's key funding program for research and innovation, offering substantial grants for collaborative biotech projects. It supports cross-border partnerships and focuses on societal challenges, including health, making it a valuable source for non-dilutive biotech capital.
Provides small, flexible grants to innovators in global health and development, allowing for rapid prototyping and proof-of-concept work. This program is ideal for early-stage biotech ideas that need initial validation before seeking larger, structured funding.
While NIH focuses on health, NSF supports fundamental research and development in engineering and biological sciences. Their non-dilutive grants are crucial for biotech companies developing novel devices, synthetic biology tools, or computational biology platforms.
Primarily known for awards, but also supports scientific research through grants and fellowships that recognize excellence. While less direct than SBIR, these honors provide prestige and indirect funding pathways for leading biotech researchers and innovators.
A global charitable foundation dedicated to improving human and animal health, providing substantial grants for biomedical research. They fund a wide range of projects from basic science to clinical trials, often supporting high-risk research that other investors avoid.
Offers prestigious, highly competitive grants for pioneering research across Europe, including life sciences and biotechnology. These non-dilutive funds support ambitious, individual-led projects that aim to push the boundaries of knowledge in biological systems.
Provides grants for research focused on understanding, treating, and curing cystic fibrosis. Their funding supports both basic science and translational efforts, offering non-dilutive capital to biotech firms developing CFTR modulators and related therapies.
Supports clinical and basic research into the causes and treatments of Parkinson's disease through various grant programs. They offer non-dilutive funding to accelerate the development of new therapeutic strategies and improve the lives of those affected.
Funds innovative research aimed at preventing, treating, and curing heart disease and stroke, including biomedical engineering innovations. Their grants support biotech startups developing novel cardiovascular diagnostics, devices, and therapeutic interventions.
Provides innovative, non-traditional funding for early-career cancer scientists, supporting high-risk research that may not fit standard grant models. This flexibility is valuable for biotech innovators exploring novel mechanisms of action in oncology.
Supports bold ideas in life sciences, particularly in molecular bioscience and technology development. Their grants often enable the creation of new tools and platforms that benefit the broader biotech community, offering non-dilutive support for foundational innovations.